Palsonify Logo

Now FDA Approved

GO TO PALSONIFY.COM
Palsonify Logo

Now FDA Approved

GO TO PALSONIFY.COM

Driving the Next Generation of Endocrinology Care

See our pipeline
VIEW OUR PUBLICATIONS

Singularly focused. Collectively driven.

SEE OUR VISION

Meet our inspiration

Empowering people to break through their disease.

Read More

Let’s build the future together

We are building the premier, endocrine-rooted global pharmaceutical company dedicated to improving the lives of patients. Are you fueled by an entrepreneurial passion for discovering, developing, and commercializing the next generation of therapies?

join us
What's new at Crinetics

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Acromegaly in Adults

Crinetics announced that the U.S. Food and Drug Administration (FDA) approved PALSONIFY™ (paltusotine) for the first-line treatment of adults with…

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

Crinetics announced that the U.S. FDA granted Orphan Drug Designation for atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor…

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Crinetics Pharmaceuticals reports second quarter 2025 financial results and provided a business update on August 7, 2025 at 4:30PM ET.

view more news & media